
Lirafugratinib + LITESPARK011
OncoPharm
00:00
Overall Survival Remains Immature
John Bazar discusses immature overall-survival data, subsequent therapies, and uncertainty about whether the combination will ultimately improve survival over cabozantinib.
Play episode from 13:40
Transcript


